Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

Author:

Balcerek Joanna,Shy Brian R.,Putnam Amy L.,Masiello Lisa M.,Lares Angela,Dekovic Florinna,Acevedo Luis,Lee Michael R.,Nguyen Vinh,Liu Weihong,Paruthiyil Sreenivasan,Xu Jingying,Leinbach Ashley S.,Bluestone Jeffrey A.,Tang Qizhi,Esensten Jonathan H.

Abstract

We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing batch records and entered into a secure database. Overall, 88% (36/41) of PolyTreg products met release criteria and 83% (34/41) of products were successfully infused into patients. Of the 7 not infused, 5 failed release criteria, and 2 were not infused because the patient became ineligible due to a change in clinical status. The median fold expansion over the 14-day manufacturing process was 434.8 -fold (range 29.8-2,232), resulting in a median post-expansion cell count of 1,841 x 106 (range 56.9-16,179 x 106). The main correlate of post-expansion cell number was starting cell number, which positively correlates with absolute circulating Treg cell count. Other parameters, including date of PolyTreg production, patient sex, and patient age did not significantly correlate with fold expansion of Treg during product manufacturing. In conclusion, PolyTreg manufacturing outcomes are consistent across trials and dates of production.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference22 articles.

1. Regulatory T-Cell Therapy for Autoimmune and Autoinflammatory Diseases: The Next Frontier;Esensten;J Allergy Clin Immunol,2018

2. Regulatory T Cells in Autoimmune Disease;Dominguez-Villar;Nat Immunol,2018

3. Regulatory T-Cell Therapy in Transplantation: Moving to the Clinic;Tang;Cold Spring Harbor Perspect Med [Internet],2013

4. Regulatory T Cells and Human Disease;Sakaguchi;Annu Rev Immunol [Internet],2020

5. Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus;Dall’Era;Arthritis Rheumatol [Internet],2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3